Transdermal Estradiol Patch Using Acrylic-Silicone Adhesive Blend
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing smaller transdermal drug delivery systems for estrogen that maintain desired pharmacokinetic properties and daily dosages while minimizing size and manufacturing costs is challenging due to the need to balance factors like delivery rate, daily dose, and patient comfort.
Innovation Solution
A transdermal drug delivery system with a polymer matrix comprising estradiol, a blend of acrylic and silicone adhesives, and soluble PVP, which achieves increased estradiol flux and coat weight, allowing for smaller system sizes without sacrificing daily dosages, by optimizing the coat weight and adhesive composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If the transdermal system size is reduced to lower costs and improve patient comfort, then the system becomes more economical and aesthetically pleasing, but achieving desired drug delivery rates and daily dosages becomes more difficult
Solution Approach 1:
The patent changes the concentration parameter of estradiol in the adhesive layer from conventional levels to greater than 0.156 mg/cm², and modifies the adhesive composition parameters (acrylic:silicone ratio, PVP content, penetration enhancers) to achieve higher flux per unit area while maintaining smaller system size
Solution Approach 2:
The patent uses a composite adhesive system combining acrylic adhesive, silicone adhesive, and soluble PVP in specific ratios, along with penetration enhancers like oleyl alcohol and dipropylene glycol, to create a material that achieves superior drug delivery performance in a smaller area
2Quantity of substance
If the estradiol concentration in the adhesive layer is increased to achieve higher flux in smaller systems, then smaller device sizes become feasible, but drug stability and solubility become more challenging
Solution Approach 1:
The patent introduces soluble PVP as an intermediary substance that stabilizes high concentrations of estradiol in the adhesive matrix, preventing crystallization and maintaining drug availability. Penetration enhancers like oleyl alcohol also act as intermediaries to facilitate drug release while maintaining stability
Solution Approach 2:
The patent modifies the chemical environment parameters of the adhesive layer by adjusting pH, solvent composition, and polymer matrix properties to maintain estradiol stability at elevated concentrations greater than 0.156 mg/cm²
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves estradiol flux rates greater than existing products, enabling comparable daily dosages in smaller devices, thus addressing the challenge of size and cost while maintaining therapeutic effectiveness.
Implementation Method 1
achieves an estradiol flux that is greater than 0.01 mg/cm2/day
Implementation Method 2
polymer matrix comprises a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble PVP
Data Source
AI summary
Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.